North America Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Country and Growth Forecast, 2022 - 2028

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cancer Gene Therapy Market, by Therapy
1.4.2 North America Cancer Gene Therapy Market, by End User
1.4.3 North America Cancer Gene Therapy Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Cancer Gene Therapy Market by Therapy
3.1 North America Gene Induced Immunotherapy Market by Country
3.2 North America Oncolytic Virotherapy Market by Country
3.3 North America Gene Transfer Market by Country
Chapter 4. North America Cancer Gene Therapy Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Diagnostic centers Market by Country
4.3 North America Research Institutes Market by Country

Chapter 5. North America Cancer Gene Therapy Market by Country
5.1 US Cancer Gene Therapy Market
5.1.1 US Cancer Gene Therapy Market by Therapy
5.1.2 US Cancer Gene Therapy Market by End User
5.2 Canada Cancer Gene Therapy Market
5.2.1 Canada Cancer Gene Therapy Market by Therapy
5.2.2 Canada Cancer Gene Therapy Market by End User
5.3 Mexico Cancer Gene Therapy Market
5.3.1 Mexico Cancer Gene Therapy Market by Therapy
5.3.2 Mexico Cancer Gene Therapy Market by End User
5.4 Rest of North America Cancer Gene Therapy Market
5.4.1 Rest of North America Cancer Gene Therapy Market by Therapy
5.4.2 Rest of North America Cancer Gene Therapy Market by End User

Chapter 6. Company Profiles
6.1 Novartis AG
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Amgen, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
6.6.1 Company overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Genelux Corporation
6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses